Accuracy, precision, and clinical laboratory utility of the TDX (Abbott Laboratories), Auto-ICS (Beckman Instruments, Inc.), COBAS-Bio (Roche Analytical Instruments, Inc.) with reagent kits (Syva), and EMIT (Syva) for gentamicin and tobramycin serum assay were assessed. TDX, COBAS-Bio, and EMIT analytical systems showed a proportional bias of less than 10% for recovery studies and a coefficient of variation less than 5% for within-run precision. The results of the recovery studies with the Auto-ICS showed a proportional bias of 25% with gentamicin and 16% with tobramycin. The within-run precision expressed as the coefficient of variation for the Auto-ICS was 6.7% for gentamicin and 8.6% for tobramycin. In comparisons involving gentamicin-and tobramycin-containing patient samples, the results with the TDX analytical system showed the best agreement with the COBAS-Bio. For the determination of these two antibiotics, the TDX analytical system provided the best overall accuracy and precision.
Aminoglycosides continue to be widely used for the treatment of serious gram-negative rod infections. Because of their relatively low toxicto-therapeutic ratio and the relative unreliability of existent dosage nomograms, the monitoring of serum aminoglycoside levels to assure adequate, nontoxic drug levels remains necessary. New instrumentation capable of making such measurements continues to be developed. It is the purpose of this paper to compare the accuracy, precision, and clinical laboratory utility of the TDX (Abbott Laboratories, Diagnostics Division, Irving, Tex.), Auto-ICS (Beckman Instruments, Inc., Brea, Calif.), COBAS-Bio (Roche Analytical Instruments, Inc., Nutley, N.J.), and EMIT (Syva, Palo Alto, Calif.) procedure for determination of serum gentamicin and tobramycin levels.
MATERIALS AND METHODS
Drug preparation. Gentamicin sulfate powder (Schering Corp., Kenilworth, N.J.) was dried for 3 h at 110°C and dissolved in a stock human serum pool to final concentrations of 5.0, 5.6, 6.7, and 10.0 ,u.g/ml. A pool containing 1.1 ,ug of drug per ml was made by diluting the 5.6-,ug/ml pool with the stock serum pool. A 3.4-,ug/ml pool was made by combining a portion of the 1.1-and 5.6-p.g/ml pools 1:1 (vol/vol).
Tobramycin powder (Eli Lilly & Co., Indianapolis, Ind.) was dried for 3 h under vacuum at 60°C and dissolved in a stock human serum pool to final concentrations of 10 and 12 ,ug/ml. A pool containing 2 ,ug of drug per ml was made by diluting the 10-p.g/ml pool with the stock serum pool. A 6-,ug/ml pool was prepared by combining portions of the 2-and 10-,ug/ml pools 1:1 (vol/vol). All gentamicin and tobramycin pools were portioned into 3-ml samples and stored at -70°C until just before use.
Patient samples. A total of 68 serum samples were selected from Clinical Center patients who were receiving gentamicin, and a total of 50 serum samples were selected from Clinical Center patients who were receiving tobramycin. Samples had been frozen at -20°C for not more than 3 months and then at -70°C for not more than 9 months in screw-capped glass vials. Samples were selected from stored patient sera previously assayed by our routine EMIT procedure to include an evenly distributed range of gentamicin and tobramycin concentrations from 1.0 to 10.0 ,ug/ml. All samples were analyzed on the day the specimens were thawed, and all specimens were analyzed on all instruments, including a repeat analysis by the EMIT procedure. Data from this repeated EMIT procedure were utilized in this study.
EMIT. EMIT (Syva) was performed according to the directions of the manufacturer (Syva) of the reagents, except for establishing a new standard curve at the beginning of each working day. In our laboratory, the gentamicin standard curve is put in every other day unless the 6.0-,ug/ml control is out of range. The tobramycin standard curve is put in once a week unless the 6.0-,ug/ml control is out of range. Nearly all of the recovery and precision study values were determined by using a new standard curve, and all of the patient values were determined by using a new curve. The principle of this procedure involves competitive binding between an aminoglycoside in a sample and a known amount of enzyme-labeled aminoglycoside for an aminoglycoside antibody. Binding of the enzymelabeled aminoglycoside decreases the activity of Tables 1 and 2 show the results of the gentamicin recovery and precision studies. For the recovery study (Table 1) determinations were performed on 9 or 10 separate days. The TDX analytical system showed the smallest proportional bias (4%). The COBAS-Bio and EMIT analytical systems had a negative proportional bias of 7%, but the Auto-ICS had a positive proportional bias of 25%. The Auto-ICS showed no systematic bias (intercept of zero), and the TDX showed a small systematic bias compared with the EMIT and the COBAS-Bio. The TDX showed the best overall among-day precision for the five different concentrations of gentamicin in that the coefficient of variation did not exceed 10%. The other three analytical systems showed a coefficient of variation greater than 10%o for one or more of the gentamicin concentrations.
RESULTS
The within-run precision ( 5% for the TDX, COBAS-Bio, and EMIT but greater than 5% for the Auto-ICS. Tables 2 and 3 show the results of the tobramycin recovery and precision studies. For the recovery study (Table 3 ) determinations were performed on 4 separate days. The TDX, CO-BAS-Bio, and EMIT showed a proportional bias of less than 10%, but the Auto-ICS had a proportional bias of 16%. The Auto-ICS had the smallest systematic bias. The EMIT system showed the best among-day precision. The TDX and COBAS-Bio showed a within-run precision (Table 2) less than 5%, but the Auto-ICS showed a within-run precision greater than 5%.
The TDX analytical system was compared with the other three analytical systems by using patient specimens containing either gentamicin or tobramycin. The TDX was chosen as the system for comparison, since the results of the recovery studies showed the best accuracy for both antibiotics. Table 4 and Fig. 1 show the results of the statistical analysis of the data obtained from 68 gentamicin-containing patient samples by using a debiased linear regression analysis (assumes random error for both the abscissa and the ordinate) (1). The EMIT system showed the greatest proportional bias (-19%) and the largest intercept (0.68 ,ug/ml) compared with the TDX. The COBAS-Bio and Auto-ICS had a proportional bias of less than 10% and an of the scatter of data points around the regression line) (2) .
The results of the statistical analysis of data obtained from 50 tobramycin-containing patient samples by a debiased linear regression method is shown in Table 5 and Fig. 2 . The COBAS-Bio and EMIT analytical systems show a proportional bias of less than 10% compared with the TDX. The Auto-ICS had a proportional bias of 22%. The intercepts were acceptable for all three systems. The largest standard error of the regression was found with the Auto-ICS system. There does appear to be an "outlier" for the Auto-ICS (Fig. 2) . If this value is deleted from the analysis, the slope comparing the Auto-ICS with the TDX becomes 1.11, reducing the proportional bias by 50%.
The problem with precision identified by this study for the Auto-ICS was evaluated by Beckman Instruments. The Auto-ICS instrument used by us for this study washed the pipette tip with a solution containing polyethylene glycol. Beckman Instruments determined that small but varying concentrations of polyethylene glycol were delivered to the reaction cell, which affected the rate of the antigen-antibody reaction and led to the problem with precision. Beckman Instruments made a modification of the Auto-ICS to wash the pipette tip with buffer solution which is free of polyethylene glycol. With a modified instrument, we repeated the within-run precision study, using tobramycin at a concentration of 6.0 ,ug/ml. Twenty consecutive determinations of this specimen gave a mean value of 7.7 ,ug/ml, a standard deviation of 0.29, and a the measurement of aminoglycoside serum levels (3, 6) , cost and time constraints prevented us from performing radioimmunoassays on the samples used in this study. As the TDX showed the best accuracy (the least proportional bias) of the systems tested for gentamicin and tobramycin measurement, we elected to compare the results obtained on patient samples with the other systems to the results obtained with the TDX. In the recovery studies, among-day precision (coefficient of variation) was greater than 10% at some concentrations of gentamicin or tobramycin for all the systems. As only 4 determinations were performed for tobramycin as compared with 9 or 10 for gentamicin, the among-day precision data for gentamicin are more reliable than those for tobramycin. Our results suggest that for aminoglycoside determination it is not realistic to expect among-day precision to be less than 10% throughout the range of measurement. Only the TDX had among-day precision values less than 10% at all concentrations of gentamicin assayed; only the EMIT had among-day precision values less than 10% at all concentrations of tobramycin assayed. In the recovery studies, the Auto-ICS showed the largest proportional bias and overall showed the poorest among-day precision, with values greater than 10% at four of the five concentrations of gentamicin and two of the four concentrations of tobramycin assayed. In the within-run precision studies, the Auto-ICS also showed the largest deviation from the target values and the largest coefficient of variation. The subsequent modification of the instrument by Beckman Instruments improved the precision (decreased the coefficient of variation), but the magnitude of deviation from the target value in fact increased.
In the analysis of the data from the patient samples, the EMIT showed for gentamicin the largest proportional bias (-19%) and the largest systematic bias (intercept of 0.68) compared with the TDX. The reason for the large proportional and systematic biases with the EMIT is not clear and is surprising in view of the good correlation obtained with the EMIT versus radioimmunoassay in other studies (4, 5) . We have previously evaluated the EMIT procedure (5), although we did not use the CP-5000 EMIT clinical processor in that study; this instrument considerably facilitates data handling, obviating the need for manual curve plotting and providing a direct print-out of results. The COBAS-Bio, which uses the EMIT reagents but in much lower volumes per test, allows a considerable reagent cost-saving per test. The TDX is the simplest instrument to operate, and would seem particularly suitable for high-volume laboratories or those with a low volume of aminoglycoside determinations but a high enough volume of the other analytes which the instrument is capable of determining to justify its purchase cost. Since this evaluation, Abbott Laboratories has employed a different curve fit procedure to improve further the precision of the TDX at both the higher and lower ends of the gentamicin and tobramycin concentration ranges.
